Physician profile
Krishna Arvind Patel
NPI 1619263183
$2,156.64
in general payments reported to CMS, 2019-2025
37 companies · $676 in 2025
The $676 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $304 · 2023: $286 · 2024: $878 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,823.35 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $240.64 | 2022-2025 | Opdualag, Krazati, Opdivo |
| Genzyme Corporation | $228.94 | 2022-2025 | |
| Pfizer INC. | $179.70 | 2023-2025 | |
| Lilly USA, LLC | $121.57 | 2022 | |
| Janssen Biotech, INC. | $121.03 | 2022-2025 | Carvykti, Tecvayli, Darzalex |
| Regeneron Healthcare Solutions, INC. | $107.13 | 2024-2025 | Libtayo, Lynozyfic |
| Intera Oncology, INC | $106.78 | 2024 | Intera |
| Merck Sharp & Dohme LLC | $80.97 | 2023-2024 | Lynparza, Keytruda, Prevymis |
| Novartis Pharmaceuticals Corporation | $76.21 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $61.65 | 2024-2025 | Enhertu |
| Glaxosmithkline, LLC. | $61.51 | 2023-2025 | Jemperli, Ojjaara |
| Celgene Corporation | $61.06 | 2024-2025 | Opdivo, Opdualag, Pomalyst |
| Sobi, INC | $55.83 | 2025 | |
| Astellas Pharma US INC | $55.36 | 2024-2025 | Padcev |
| Immunocore Limited | $50.00 | 2023 | Kimmtrak |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $44.95 | 2022-2024 | Monjuvi |
| Array Biopharma INC | $44.62 | 2024 | Mektovi, Braftovi, Lorbrena |
| Boston Scientific Corporation | $35.23 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Abbvie INC. | $34.65 | 2025 | |
| Daiichi Sankyo INC. | $29.47 | 2025 | Vanflyta |
| Eisai INC. | $29.42 | 2024 | |
| Tersera Therapeutics LLC | $29.14 | 2025 | Zoladex |
| Pharmaessentia USA Corporation | $29.07 | 2024 | Besremi |
| Fennec Pharmaceuticals, INC. | $25.46 | 2025 | Fyarro |
| Genentech USA, INC. | $25.07 | 2024 | Polivy, Tecentriq |
| Morphosys, US INC. | $24.75 | 2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $23.61 | 2023 | Fotivda |
| Servier Pharmaceuticals LLC | $22.97 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.44 | 2022 | |
| Puma Biotechnology, INC. | $19.26 | 2024 | |
| Seagen INC. | $18.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.59 | 2023 | Gilotrif |
| Emd Serono, INC. | $15.78 | 2023 | Tepmetko |
| Kyowa Kirin, INC. | $15.60 | 2024 | Poteligeo |
| Amgen INC. | $15.40 | 2022 | |
| Caris Mpi, INC. | $14.19 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.